Validated biomarkers are an essential and often under-appreciated tool for detecting and treating diseases, improving drug development, and informing regulatory decision making. Recent advances in genetic and molecular technologies are leading to the identification of sensitive, specific, and validated biomarkers for numerous diseases, including multiple sclerosis, pancreatic cancer, Alzheimer's disease, and more. Development of biomarkers that rely on digital technologies are of great interest to many stakeholders. What is new and promising in this realm of critical tools for the biomedical innovation ecosystem? Are issues of access to these tools by physicians and patients being addressed?

Moderator

Charles Ryan

President and CEO, Prostate Cancer Foundation

Speakers

Mark Allegretta

Vice President, Research, National MS Society

Namandje Bumpus

Chief Scientist, US Food and Drug Administration

Julie Louise Gerberding

CEO, Foundation for the National Institutes of Health

Varun Renjen

Managing Director-Health Care and Life Sciences Deal Advisory and Strategy, KPMG